These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cardiac transplantation in over 1000 patients: a single institution experience from Columbia University. Edwards NM; Rajasinghe HA; John R; Chen JM; Itescu S; Mancini DM Clin Transpl; 1999; ():249-61. PubMed ID: 11038644 [TBL] [Abstract][Full Text] [Related]
23. Immune monitoring of blood in heart transplant recipients: application of flow cytometry. Garner RJ; Springgate C; Hoyt T Semin Diagn Pathol; 1989 Feb; 6(1):83-90. PubMed ID: 2645626 [TBL] [Abstract][Full Text] [Related]
24. The role of right ventricular endomyocardial biopsy in the long-term management of heart-lung transplant recipients. Glanville AR; Imoto E; Baldwin JC; Billingham ME; Theodore J; Robin ED J Heart Transplant; 1987; 6(6):357-61. PubMed ID: 3121820 [TBL] [Abstract][Full Text] [Related]
26. Selective use of OKT3 in heart transplantation with the use of risk factor analysis. Macris MP; Van Buren CT; Sweeney MS; Frazier OH; Duncan JM J Heart Transplant; 1989; 8(4):296-302. PubMed ID: 2504896 [TBL] [Abstract][Full Text] [Related]
27. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation. Valantine H; Zuckermann A J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320 [TBL] [Abstract][Full Text] [Related]
28. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. Rinaldi M; Pellegrini C; Martinelli L; Goggi C; Gavazzi A; Campana C; Arbustini E; Grossi P; Regazzi M; Ippoliti G; Vigano M J Heart Lung Transplant; 1997 Oct; 16(10):1001-10. PubMed ID: 9361242 [TBL] [Abstract][Full Text] [Related]
29. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. Valantine H J Heart Lung Transplant; 2004 May; 23(5 Suppl):S187-93. PubMed ID: 15093804 [TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience. Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895 [TBL] [Abstract][Full Text] [Related]
32. Diagnostic validity of hepatocyte growth factor as marker for rejection in the follow-up of patients after heart transplantation. Zwirska-Korczala K; Zakliczyński M; Berdowska A; Zembala M; Jochem J; Gajewska K J Heart Lung Transplant; 2005 Apr; 24(4):411-5. PubMed ID: 15797741 [TBL] [Abstract][Full Text] [Related]
33. Acute rejection and heart infection rates in FK 506- versus cyclosporine A-treated heart transplant recipients: an endomyocardial biopsy pathologic study. Arbustini E; Dal Bello B; Rinaldi M; Diegoli M; Grasso M; Pellegrini C; Morbini P; Martinelli L; Bonora MR; Viganò M J Heart Lung Transplant; 1997 Sep; 16(9):982-4. PubMed ID: 9322152 [No Abstract] [Full Text] [Related]
34. Heart-lung transplantation: an overview. Starnes VA Cardiol Clin; 1990 Feb; 8(1):159-68. PubMed ID: 2407357 [TBL] [Abstract][Full Text] [Related]